"It is an amazing privilege to work with such talented and creative researchers across Genentech to advance meaningful therapies for patients."
Motivated by Genentech’s focus on patients and scientific excellence, I joined the Department of Protein Chemistry in 2014 after working for eleven years developing antibody-drug conjugates at ImmunoGen.
The Department of Protein Chemistry utilizes recombinant protein and bioconjugation expertise to design and produce novel therapeutic candidates for the treatment of diseases with high unmet clinical need.
Bioconjug Chem. 2017 Oct 18;28(10):2538-2548.
My primary role is to direct the activities of the Department of Protein Chemistry. My research lab is focused on understanding the key biological mechanisms associated with our leading therapeutic candidates in Molecular Oncology. We collaborate closely with colleagues across the research community in this pursuit. Recently, we explored how the selection of the mutation sites impacts the stability of cysteine-engineered antibody-drug conjugates.
Our current interests are focused on deepening our mechanistic understanding of T cell-directed therapies using biochemical and biophysical approaches.